- Report
- May 2025
North America
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- May 2025
Middle East
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- May 2025
Asia Pacific
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- May 2025
United States
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- May 2025
United Kingdom
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- May 2025
North America
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
From €1939EUR$2,095USD£1,631GBP
€3693EUR$3,990USD£3,106GBP
- Report
- December 2024
- 150 Pages
Global
From €3107EUR$3,358USD£2,613GBP
€3656EUR$3,950USD£3,075GBP
- Report
- October 2023
- 146 Pages
Global
From €3265EUR$3,528USD£2,746GBP
€3841EUR$4,150USD£3,230GBP
- Report
- October 2023
- 146 Pages
Global
From €3265EUR$3,528USD£2,746GBP
€3841EUR$4,150USD£3,230GBP
- Report
- February 2025
- 90 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- January 2025
- 159 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- October 2024
- 92 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- October 2024
- 86 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- October 2024
- 89 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- October 2024
- 86 Pages
Global
From €3500EUR$4,051USD£3,047GBP
- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,051USD£3,047GBP

The biopharmaceuticals market is a sector of the pharmaceutical industry that focuses on the development and production of drugs derived from biological sources. These drugs are typically produced using recombinant DNA technology, which involves the manipulation of genetic material to create proteins and other molecules with therapeutic properties. Biopharmaceuticals are used to treat a wide range of diseases, including cancer, HIV/AIDS, and autoimmune disorders.
Biopharmaceuticals are typically more expensive to produce than traditional pharmaceuticals, but they offer a number of advantages, such as improved efficacy and fewer side effects. They are also more targeted, meaning they can be used to treat specific conditions more effectively.
Some of the major companies in the biopharmaceuticals market include Amgen, Biogen, Celgene, Gilead Sciences, and Novartis. These companies are involved in the development and production of a wide range of biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies. Show Less Read more